Fig. 2

Portal and periportal inflammation has disappeared at 12 months after BMMNC administration. A Moderate portal and periportal inflammation with dense infiltration of lymphocytes and plasma cells. B Inflammatory cells can no longer be observed in the portal and periportal areas